|Videos|March 16, 2016

How Can Pharmacists Aid in Controlling the Spread of the Zika virus?

Jason C. Gallagher, PharmD describes how pharmacists can aid in controlling the spread of the Zika virus.

Jason C. Gallagher, PharmD, FCCP, BCPS, Clinical Professor at the Temple University School of Pharmacy and a Clinical Pharmacy Specialist in Infectious Diseases at Temple University Hospital describes how pharmacists can aid in controlling the spread of the Zika virus.

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Subscribe Now!

How Can Pharmacists Aid in Controlling the Spread of the Zika virus?

Newsletter

Related Content

Recent Florida Cases of Chikungunya Linked to Cuba Travelers, Reminder Vector-Borne Illness is Still Circulating

Caring Holistically: NYU’s Approach to Pediatric Infectious Disease

A Pediatrician’s Perspective on the Latest ACIP Hepatitis B Vaccine Recommendations

Working With Young Clinicians to Identify, Treat Vector-Borne Diseases

NYU’s Vaccine Center: A Short History With Significant Contributions

Latest CME

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Kentucky

(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?

Tackling Oncologic Emergencies in Patients Treated with High-Dose Methotrexate

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Indiana

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies

Rapid Reviews in Retina™: Emerging Updates from Fall 2024 - Addressing the Wealth of New Data in Treatments for nAMD and DME

Medical Crossfire®: Optimal Approaches to Evaluating and Addressing Pain in the Patient With Sickle Cell Disease

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer

Community Practice Connections™: 21st Annual Meeting of the International Society of Gastrointestinal Oncology

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Missouri

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | New Mexico

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Clinical Case Vignette Series™: 3rd Annual International Congress on Pediatric Oncology

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

22nd Annual Meeting of the International Society of Gastrointestinal Oncology

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | North Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | West Virginia

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Tennessee

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Washington

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | South Carolina

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Texas

Cases and Conversations™: Optimizing Patient Outcomes in Pediatric/AYA and Adult ALL/LBL With Asparaginase Therapies and Combinations

Advances in ALL Management Across the Patient Spectrum: Integrating Innovation and Precision Care

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Nevada

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

How We Do It®: New Combinations Reshaping Treatment Decision-Making in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: Bridging Expert Guidance and Evidence-Based Recommendations in the Ever-Evolving Treatment of MF, PV, and ET

From Barriers to Breakthroughs in Multiple Myeloma: How Trials Compare to the Real-World Management of Patients in Your Practice

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies and Trials Across GvHD Prophylaxis, Acute, and Chronic Care?

Medical Crossfire®: New Horizons in Acute Lymphoblastic Leukemia—How The Experts Apply New Evidence from AYA to Adult Scenarios

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kentucky

Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next in B-Cell Malignancies

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

DSUI Urology on the Beach

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Minnesota

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

23rd Annual Winter Lung Cancer Conference®

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

Cases and Conversations™: The Rationale for Utilizing Nonfactor Replacement Therapies in Hemophilia Care

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

EnVision Summit

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

30th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Patient, Provider, and Caregiver Connection: Improving Diagnosis and Care for Adolescent Myasthenia Gravis Patients – A New Frontier

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Burst CME™: Stepping Up Care for Patients With PAH

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME